title: Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
abstract: Despite all the knowledge, the cellular and molecular mechanisms involved in myeloproliferative neoplasm (MPN) pathophysiology remain unclear. Authors have shown galectin-1 (Gal-1) and 3 playing roles in tumour angiogenesis and fibrosis, which were correlated with poor prognosis in patients with MPN. In the present study LGALS1 and LGALS3 were differently expressed between polycythemia vera, essential thrombocythemia (ET) and primary myelofibrosis (PMF) diseases. Increased LGALS3 expression was associated with a negative JAK2 V617F status mutation in leucocytes from PMF but not in patients with ET without this mutation. However, a positive Janus kinase 2 (JAK2) V617F cell line established from patients with ET (SET-2 cells) when treated with JAK inhibitor presented high levels of LGALS3. Additionally, high LGALS1 expression was found in CD34(+) cells but not in leucocytes from patients with PMF, in absence of JAK2 V617F mutation, and also in SET-2 cells treated with JAK inhibitor. Thus, our findings indicate that differential expression of LGALS1 and/or LGALS3 in patients with MPN is linked with JAK2 V617F status mutation in these diseases and state of cell differentiation.
authors.affiliation: Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil.
authors.forename: L G
authors.initials: LG
authors.lastname: Moura
authors.affiliation: Departamento de Farmácia, Universidade Federal de Juiz de Fora-Campus Governador Valadares, Governador Valadares, Minas Gerais, Brasil.
authors.forename: R
authors.initials: R
authors.lastname: Tognon
authors.affiliation: Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil.
authors.forename: N S
authors.initials: NS
authors.lastname: Nunes
authors.affiliation: Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil.
authors.forename: L Cataldi
authors.initials: LC
authors.lastname: Rodrigues
authors.affiliation: Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil.
authors.forename: A F
authors.initials: AF
authors.lastname: Ferreira
authors.affiliation: Hemocentro de Ribeirão Preto-Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil.
authors.forename: S
authors.initials: S
authors.lastname: Kashima
authors.affiliation: Hemocentro de Ribeirão Preto-Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil.
authors.forename: D T
authors.initials: DT
authors.lastname: Covas
authors.affiliation: Hospital Estadual de Transplantes Euryclides de Jesus Zerbini, São Paulo, Brasil.
authors.forename: M
authors.initials: M
authors.lastname: Santana
authors.affiliation: Hospital Estadual de Transplantes Euryclides de Jesus Zerbini, São Paulo, Brasil.
authors.forename: E X
authors.initials: EX
authors.lastname: Souto
authors.affiliation: Hospital Estadual de Transplantes Euryclides de Jesus Zerbini, São Paulo, Brasil.
authors.forename: L
authors.initials: L
authors.lastname: Perobelli
authors.affiliation: Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil.
authors.forename: B P
authors.initials: BP
authors.lastname: Simões
authors.affiliation: Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil.
authors.forename: M
authors.initials: M
authors.lastname: Dias-Baruffi
authors.affiliation: Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil.
authors.forename: F A
authors.initials: FA
authors.lastname: Castro
mesh_terms: D000328:Adult; D019943:Amino Acid Substitution; D018952:Antigens, CD34 / Q000235:genetics; D001798:Blood Proteins; D001853:Bone Marrow / Q000473:pathology; D019046:Bone Marrow Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism; D002460:Cell Line; D037483:Galectin 1 / Q000235:genetics* / Q000378:metabolism; D037502:Galectin 3 / Q000235:genetics* / Q000378:metabolism; D037161:Galectins; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism; D011087:Polycythemia Vera / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism; D013920:Thrombocythemia, Essential / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism
chemical_list: D018952:Antigens, CD34; D001798:Blood Proteins; D037483:Galectin 1; D037502:Galectin 3; D037161:Galectins; C445499:LGALS1 protein, human; C428445:LGALS3 protein, human; C507924:JAK2 protein, human; D053614:Janus Kinase 2
keywords: CANCER GENETICS; GENE AMPLIFICATION; HAEMATO-ONCOLOGY